NCL Inhibition Exerts Antineoplastic Effects against Prostate Cancer Cells by Modulating Oncogenic MicroRNAs
Open Access
- 10 July 2020
- Vol. 12 (7), 1861
- https://doi.org/10.3390/cancers12071861
Abstract
Prostate cancer (PCa) is the most frequently diagnosed cancer in men and second most common cause of cancer-related deaths in the United States. Androgen deprivation therapy (ADT) is only temporarily effective for advanced-stage PCa, as the disease inevitably progresses to castration-resistant prostate cancer (CRPC). The protein nucleolin (NCL) is overexpressed in several types of human tumors where it is also mislocalized to the cell surface. We previously reported the identification of a single-chain fragment variable (scFv) immuno-agent that is able to bind NCL on the surface of breast cancer cells and inhibit proliferation both in vitro and in vivo. In the present study, we evaluated whether NCL could be a valid therapeutic target for PCa, utilizing DU145, PC3 (CRPC), and LNCaP (androgen-sensitive) cell lines. First, we interrogated the publicly available databases and noted that higher NCL mRNA levels are associated with higher Gleason Scores as well as with recurrent and metastatic tumors. Then, using our anti-NCL scFv, we demonstrated that NCL is expressed on the surface of all three tested cell lines and that NCL inhibition results in reduced proliferation and migration. We also measured the inhibitory effect of NCL targeting on the biogenesis of oncogenic microRNAs such as miR-21, -221 and -222, which was cell context dependent. Taken together, our data provide evidence that NCL targeting inhibits the key hallmarks of malignancy in PCa cells and may provide a novel therapeutic option for patients with advanced-stage PCa.Funding Information
- National Institutes of Health (NIH R35CA197706)
This publication has 74 references indexed in Scilit:
- In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulationThe Journal of Experimental Medicine, 2013
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- Enhanced translation by Nucleolin via G-rich elements in coding and non-coding regions of target mRNAsNucleic Acids Research, 2011
- A New Paradigm for Aptamer Therapeutic AS1411 Action: Uptake by Macropinocytosis and Its Stimulation by a Nucleolin-Dependent MechanismCancer Research, 2010
- miR-21: An Androgen Receptor–Regulated MicroRNA that Promotes Hormone-Dependent and Hormone-Independent Prostate Cancer GrowthCancer Research, 2009
- Optimizing molecular signatures for predicting prostate cancer recurrenceThe Prostate, 2009
- The Role of microRNA-221 and microRNA-222 in Androgen-Independent Prostate Cancer Cell LinesCancer Research, 2009
- Cell-surface nucleolin is a signal transducing P-selectin binding protein for human colon carcinoma cellsExperimental Cell Research, 2008
- Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferationThe EMBO Journal, 2007
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006